These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 23400965)

  • 1. Pilot study of H₂ therapy in Parkinson's disease: a randomized double-blind placebo-controlled trial.
    Yoritaka A; Takanashi M; Hirayama M; Nakahara T; Ohta S; Hattori N
    Mov Disord; 2013 Jun; 28(6):836-9. PubMed ID: 23400965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized double-blind multi-center trial of hydrogen water for Parkinson's disease: protocol and baseline characteristics.
    Yoritaka A; Abe T; Ohtsuka C; Maeda T; Hirayama M; Watanabe H; Saiki H; Oyama G; Fukae J; Shimo Y; Hatano T; Kawajiri S; Okuma Y; Machida Y; Miwa H; Suzuki C; Kazama A; Tomiyama M; Kihara T; Hirasawa M; Shimura H; Hattori N
    BMC Neurol; 2016 May; 16():66. PubMed ID: 27176725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
    Rascol O; Fitzer-Attas CJ; Hauser R; Jankovic J; Lang A; Langston JW; Melamed E; Poewe W; Stocchi F; Tolosa E; Eyal E; Weiss YM; Olanow CW
    Lancet Neurol; 2011 May; 10(5):415-23. PubMed ID: 21482191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease.
    Yoritaka A; Kawajiri S; Yamamoto Y; Nakahara T; Ando M; Hashimoto K; Nagase M; Saito Y; Hattori N
    Parkinsonism Relat Disord; 2015 Aug; 21(8):911-6. PubMed ID: 26054881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.
    Hauser RA; Panisset M; Abbruzzese G; Mancione L; Dronamraju N; Kakarieka A;
    Mov Disord; 2009 Mar; 24(4):541-50. PubMed ID: 19058133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease.
    Hauser RA; Lyons KE; McClain T; Carter S; Perlmutter D
    Mov Disord; 2009 May; 24(7):979-83. PubMed ID: 19230029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.
    Hauser RA; Schapira AH; Rascol O; Barone P; Mizuno Y; Salin L; Haaksma M; Juhel N; Poewe W
    Mov Disord; 2010 Nov; 25(15):2542-9. PubMed ID: 20669317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group
    Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rotigotine vs ropinirole in advanced stage Parkinson's disease: a double-blind study.
    Mizuno Y; Nomoto M; Hasegawa K; Hattori N; Kondo T; Murata M; Takeuchi M; Takahashi M; Tomida T;
    Parkinsonism Relat Disord; 2014 Dec; 20(12):1388-93. PubMed ID: 25455692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
    Olanow CW; Kieburtz K; Stern M; Watts R; Langston JW; Guarnieri M; Hubble J;
    Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
    Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
    Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
    Rascol O; Dubois B; Caldas AC; Senn S; Del Signore S; Lees A;
    Mov Disord; 2006 Dec; 21(12):2110-5. PubMed ID: 17013922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
    Goetz CG; Damier P; Hicking C; Laska E; Müller T; Olanow CW; Rascol O; Russ H
    Mov Disord; 2007 Jan; 22(2):179-86. PubMed ID: 17094088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial.
    Rascol O; Bronzova J; Hauser RA; Lang AE; Sampaio C; Theeuwes A; van de Witte SV
    Parkinsonism Relat Disord; 2012 May; 18(4):370-6. PubMed ID: 22316635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
    Olanow CW; Hauser RA; Gauger L; Malapira T; Koller W; Hubble J; Bushenbark K; Lilienfeld D; Esterlitz J
    Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial.
    Ondo WG; Shinawi L; Moore S
    Mov Disord; 2010 Dec; 25(16):2724-7. PubMed ID: 20925074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study.
    Mizuno Y; Abe T; Hasegawa K; Kuno S; Kondo T; Yamamoto M; Nakashima M; Kanazawa I;
    Mov Disord; 2007 Oct; 22(13):1860-5. PubMed ID: 17618525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial.
    Poewe W; Rascol O; Barone P; Hauser RA; Mizuno Y; Haaksma M; Salin L; Juhel N; Schapira AH;
    Neurology; 2011 Aug; 77(8):759-66. PubMed ID: 21832218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.